Meta Information

ID:everolimus

Name:Everolimus

Schema Version:1.5

Alternate Names

• Afinitor
• Zortress
• RAD001

Active Compound

everolimus

Intervention Type

therapeutic_agent

Delivery

Route:

oral

Scope:

• systemic

Regulatory Status

• us:rx_drug
• eu:rx_drug

Indication

Focus:

• healthspan
• disease_treatment

Description:

Primarily an immunosuppressant and anti-cancer agent, but investigated for healthspan due to its inhibition of the mTOR pathway, a key regulator of aging.

Typical Protocol

• Experimental healthspan protocols often involve low, intermittent doses such as 2.5 mg to 5 mg once per week, mimicking rapamycin regimens.

Expected Cost Mean

Low Cost:

5000

High Cost:

15000

Cost Type:

monthly

Description:

Branded prescription drug; insurance covers approved indications, not off-label healthspan use.

Summary

Everolimus is a derivative of rapamycin (a 'rapalog') that potently inhibits the mTORC1 signaling pathway. This pathway is a central regulator of cellular growth, metabolism, and aging. By dampening mTOR activity, everolimus can induce autophagy (cellular cleaning) and reduce inflammation, processes thought to be fundamental to extending healthspan.

Purpose

Inhibits the mTOR pathway to slow cellular aging processes.

Card Summary

A potent mTOR inhibitor, similar to rapamycin, studied for its potential to slow aging by promoting cellular cleanup and reducing age-related inflammation.

Drug Class

mTOR_inhibitor

Drugs In Class

Empty Array

Impact

Score:

5.5

Justification:

Potent mTOR inhibitor with strong animal data, but limited human healthspan trial evidence.

Evidence

Grade:

B

Score:

6.5

Justification:

Human RCTs show improved immune function in elderly, but long-term healthspan data is lacking.

Safety

Score:

7.5

Justification:

Potent immunosuppressant with significant side effects requiring strict medical supervision for off-label use.

Flags

• Increases risk of serious infections due to its immunosuppressive effects.
• Common side effects include mouth sores (stomatitis), rash, fatigue, and diarrhea.
• Can cause significant metabolic changes, including high blood sugar and high cholesterol/triglycerides.
• Risk of rare but serious non-infectious pneumonitis (lung inflammation).
• May impair fertility in both males and females.
• Interacts with many common medications through the CYP3A4 enzyme pathway.

Verdict

A powerful but high-risk mTOR inhibitor for experimental anti-aging use.

Created

2026-05-06T16:37:55.078304Z

Ai Model

Gemini 2.5 Pro (High)